Sri Kosaraju has served on the 10x Genomics board of directors since April 2019.
Since January 2026 he has served as a global chair of investment banking for JPMorgan Chase & Co. supporting the firm's healthcare industry vertical. He was President and CEO of Inscripta from October 2020 to April 2025, when it merged with Manus Bio. Earlier he was President of Penumbra (August 2019-May 2020), its CFO (May 2015-November 2019) and Head of Strategy, and before that spent 16 years in investment banking at J.P. Morgan, ultimately as Managing Director of Equity Capital Markets and Head of Healthcare Equity Capital Markets.
He received a B.S. from the Massachusetts Institute of Technology in 1999.